32 results about "Bexarotene" patented technology

This invention describes the administration of multiple therapeutic agents with insulin in conjunction with bexarotene, ketamine, monoclonal antibodies Etanercept, IGF-1, and acetylcholine esterase inhibitors physostigmine, for treatment of Alzheimer's disease and other neurodegenerative diseases. Insulin, improves memory; also augments and amplifies the effects of the adjuvant therapeutic agents (paracrine and intracrine effects) and consequently reduces the β amyloid, its soluble precursors, prevents damage to the neuronal skeletal network (taupathy), and blocks glutamate excitotoxicity, reduces brain inflammation, prevents apoptosis, and increases the acetylcholine levels in the neurons and synapses; by using a combination of insulin, bexarotene, ketamine, Etanercept, IGF-1, and physostigmine therapeutic agents. The results are achieved by using the specially designed Iontophoresis incorporated olfactory mucosal delivery (ORE) catheter device located at the olfactory nerves, sphenoid sinus, and adjacent structures described here, to transport the large molecules of therapeutic agents to treat AD delivered to the CNS bypassing BBB from ORE.

The present invention relates to analogs of bexarotene and methods of use thereof.

Topical pharmaceutical compositions are described comprising: a) bexarotene, b) a corticosteroid, and c) a carrier or vehicle. Said compositions are useful for the treatment of skin disorders.

The present invention aims to provide a growth inhibitor for cancer stem cells resistant to existing anticancer drug therapies, which growth inhibitor acts on the cells through growth inhibition and apoptosis. The growth inhibitor for cancer stem cells contains a retinoid agonist, preferably tamibarotene, alone or in combination with a rexinoid agonist, preferably bexarotene, as an effective component(s). The growth inhibitor for cancer stem cells enhances the effects of various anticancer drugs when the growth inhibitor is used in combination with the anticancer drugs.

The present invention describes genomic biomarkers that have been discovered to correlate with varied individual responses (efficacy, adverse effect, and other end points) to therapeutic retinoid X receptor modulator, such as bexarotene, in treating diseases such as, non small cell lung cancer. The newly discovered biomarkers and others in linkage disequilibrium with them can be used in companion diagnostic tests which can help to predict drug responses and apply drugs only to those who will be benefited, or exclude those who might have adverse effects, by the treatment.

A bexarotene slow-release implant for treating solid tumors is characterized in that the slow-release implant contains an effective anticancer dose of bexarotene, a slow-release auxiliary material and a certain amount of slow-release regulator. Solid tumors include lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostate cancer, bladder cancer, and colorectal cancer. Sustained-release excipients are mainly copolymers of glycolic acid and glycolic acid, polyphenylpropanol, poly(L-lactide-co-ethyl phosphate), and poly(L-lactide-co-propyl phosphate). One or a combination thereof can slowly release bexarotene locally in the tumor during its degradation and absorption, so while significantly reducing its systemic toxicity, it can also maintain an effective drug concentration in the local tumor. Local placement of the anti-sustained-release implant in the tumor can not only reduce the systemic toxicity of bexarotene, but also selectively increase the drug concentration in the local tumor, and enhance the therapeutic effect of non-surgical treatments such as chemotherapy drugs and radiotherapy.

The invention discloses a bexarotene soft capsule and a preparation method thereof. The bexarotene soft capsule comprises: contents and a soft capsule shell, wherein the contents include bexarotene, low molecular weight polyethylene Glycols, high molecular weight polyethylene glycols, and polysorbates. The bexarotene soft capsules composed of this formula can avoid drug degradation caused by high temperature exothermic and difficult degassing during the preparation of bexarotene soft capsules in the prior art while maintaining its drug release characteristics question.